Amgen: Graves Ophthalmopathy trials

The registry lists 12 Graves Ophthalmopathy studies with Amgen as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 3Phase 2 3Phase 3 3Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseRecruitingNCT07438405Phase 2
• A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseaseCompletedNCT04583735Phase 4Results posted
• Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension StudyCompletedNCT03461211Phase 3Results posted
• Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical StudyCompletedNCT03298867Phase 3Results posted
• Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye DiseaseCompletedNCT01868997Phase 2Results posted
• A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese ParticipantsCompletedNCT07142642Phase 1
• Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease PatientsCompletedNCT07085117
• A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseActive, not recruitingNCT06401044Phase 1/2
• A Study of TEPEZZA® Treatment in Participants With Thyroid Eye DiseaseCompletedNCT06389578Phase 1
• A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye DiseaseActive, not recruitingNCT06248619Phase 3
• TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement StudyCompletedNCT05002998Phase 4
• Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseApproved for marketingNCT04040894